Live · 13 Sep 2026 SPX 7,656.98 +0.86% NDX 29,368.44 +0.91% VIX 15.84 -11.21% GOLD 4,390.00 +0.58% CL 99.99 -2.43% BTC 77,135.67 +0.74%
NAS100 29,368 +0.91% S&P 7,657 +0.86% GOLD $4,390 +0.58% BTC $77,136 +0.74% VIX 15.84 −11.21% live tape · as of 10:31 UTC
Vol. II · No. 256Sunday, 13 September 2026
TTitan Protect
The Screen · Healthcare

Silo Pharma, Inc.

SILO · Nasdaq · USD · Market cap $7M

FAIL · Does not pass the screen
5.90 USD

At the last full screen
2026-05-22

Screened 2026-05-22 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

The Label · The Season, Not the Day

This name holds its markdown label.

Silo Pharma, Inc. holds its Markdown at $5.90. The statistical read favours the sellers, held for 7 days.

As held on the ledger · 2026-05-22
PhaseMarkdown · caution
Quantitative stateThe statistical read favours the sellers, held for 7 days
Price at the screen$5.90
Valuation0.00 trailing · -0.58 forward price to earnings
Values screenFAIL
The Workings

Five Screens, Shown in Full

Does not pass. Cash ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 0.00% Below 33% Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 91.05% Below 33% Interest-bearing cash and securities are 91.0% of assets, above the one-third limit. Fail
Receivables 0.00% Below 49% Money owed to the company is 0.0% of assets, under the 49% limit. Pass
Revenue purity 0.00% Below 5% Only 0.0% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-0.6x
Trailing P/E0.0x
EPS, trailing-0.39
EPS, forward-0.70
Revenue growth+0.0%revenue is shrinking
Profit margin0.0%currently unprofitable
Return on equity-99.9%not currently earning a positive return on equity
Debt to equity0.00minimal debt: a conservative balance sheet
Market cap$7M

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

SILO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-09-12 Markdown · changed $5.90 +0.0% Entry 5

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-08-12 Markup · changed $5.90 +0.0% Entry 4

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-18 Markdown $5.90 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-03 Markdown $5.90 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markdown $5.90 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · SILO
DateInsiderTitleTypeSharesValue
2025-12-15 WEISBLUM ERIC Chief Executive Officer 5,000 $2,075
2025-11-21 WEISBLUM ERIC Chief Executive Officer 2,000 $735
2025-11-19 WEISBLUM ERIC Chief Executive Officer 12,000 $4,847
2025-05-27 WEISBLUM ERIC Chief Executive Officer 10,000 $4,329
2024-12-13 WEISBLUM ERIC Chief Executive Officer 2,500 $2,097
2024-11-22 WEISBLUM ERIC Chief Executive Officer 5,000 $4,625
2024-06-12 WEISBLUM ERIC Chief Executive Officer 5,000 $5,533

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $5.85 +9.4% · $1,094 +9.4%
2 months $6.61 -3.3% · $968 -3.3%
3 months $5.14 +24.4% · $1,244 +24.4%
6 months $6.68 -4.1% · $959 -4.1%
1 year $8.81 -27.3% · $727 -27.3%
2 years $17.70 -63.8% · $362 -63.8%
3 years $35.40 -81.9% · $181 -81.9%
5 years $213.75 -97.0% · $30 -97.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SILO does next, these words stay.

Silo Pharma, Inc. · SILO · Markdown · $5.90
Recorded 2026-05-22 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.